AARP Opposes 12-Year Exclusivity For Biologic Drugs In TPP

Law360, New York (October 24, 2013, 4:43 PM EDT) -- AARP Inc. said Tuesday that U.S. trade negotiators should not push for a provision in the Trans-Pacific Partnership that would allow brand-name biologic drugs to have exclusive access to the market for 12 years.

AARP, which represents Americans 50 and older and their families, sent a letter to U.S. Trade Representative Michael Froman saying the U.S. should not sign onto a TPP agreement that binds it to a 12-year market exclusivity period for branded biologic medicines, which can be used to treat diseases like cancer and...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.